A study to evaluate the effect of multiple doses of carbamazepine and itraconazole on how long JNJ-55308942 stays in the body (pharmacokinetics) in healthy adults.
This early-stage study aims to understand how a new medicine, called JNJ-55308942, behaves in the bodies of healthy adults. Researchers want to see if taking it with other common medicines, carbamazepine and itraconazole, changes how long JNJ-55308942 stays in the body. This is crucial because if medicines stay in the body for different lengths of time, it could affect how well they work or if they cause side effects. Although the new medicine might eventually help with conditions like bipolar depression, this particular study isn't treating that condition. Instead, it's a vital step to gather safety information and learn more about the medicine before it's tested in people with the actual illness.
At a glance
What is this study about?
Imagine your body as a system that processes medicine. When you take a pill, your body takes it in, uses what it needs, and then gets rid of it. This study is like a detective story, investigating how a new medicine, JNJ-55308942, moves through this system in healthy adults. Researchers are particularly interested in whether taking this new medicine alongside two other common medicines, carbamazepine and itraconazole, changes how quickly JNJ-55308942 is cleared from the body.
This kind of study is really important because medicines can sometimes affect each other. Think of it like cooking: adding one ingredient can change the flavour and texture of the whole dish. Similarly, taking two medicines at once can sometimes alter how each one works. By understanding these interactions early on, doctors can make sure that when JNJ-55308942 is eventually used to treat conditions like bipolar depression, it's given in a way that's as safe and effective as possible.
While the new medicine mentioned (JNJ-55308942) might one day be used for conditions like bipolar depression, this specific study isn't about treating that condition. Instead, it's a foundational step, focusing on how medicines behave in the body, which is called 'pharmacokinetics'. It helps scientists understand the basic science of the drug before it can be developed further to help people who are unwell.
Key takeaways
- This is an early-stage study (Phase I) in healthy adults.
- It aims to understand how a new medicine, JNJ-55308942, behaves in the body.
- Researchers are checking how it interacts with other common medicines.
- The findings are crucial for developing future treatments for bipolar depression.
- Participation involves taking medicines and undergoing medical checks.
Who may be eligible?
To join this study, you need to be a healthy adult aged 18 or over. This means you shouldn't have any major ongoing health problems. The researchers are looking for people who are generally well because they want to understand how the new medicine and other medicines interact without other illnesses getting in the way.
Both men and women can take part in this study. The exact health checks will be explained in full by the study team, but generally, you'll need to pass a medical check-up to make sure you're suitable.
It's important to remember that this study is for healthy volunteers, not people who are currently being treated for bipolar depression or any other condition that could affect the results.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally healthy and have no major ongoing medical conditions?
- Are you willing to take study medicines and attend regular appointments?
- Are you able to understand and sign a consent form?
What does participation involve?
If you decide to take part, you will be given the new medicine JNJ-55308942, along with carbamazepine and itraconazole, at different times. You'll have regular visits to the clinic where you might have blood samples taken to measure how much of the medicine is in your body over time. You might also have other checks like blood pressure and heart rate measurements. The exact number of visits, tests, and the total length of time you'll be involved in the study (which could vary) will be fully explained by the study team. You'll receive detailed instructions on how and when to take the medicines, and there will be follow-up appointments to make sure you're well after the study medicines have been stopped.
Potential risks and benefits
Locations (1)
- —UnverifiedBelgium
Common questions
What is JNJ-55308942?
It's a new medicine being developed that might one day help with conditions like bipolar depression. This study is just looking at how it behaves in healthy people.
Will I be treated for bipolar depression in this study?
No, this study is not for treatment. It's an early-stage study in healthy adults to understand how the medicine works in the body.
What do 'pharmacokinetics' mean?
It's a scientific term that describes how a medicine moves through your body – how it's absorbed, distributed, processed, and eventually leaves your system.
Will I have to stay in a clinic?
The study details about clinic stays or outpatient visits will be fully explained by the study team if you express interest. It varies depending on the study design.
Who is funding this study?
The study is sponsored by a pharmaceutical company, JNJ, which is developing the new medicine.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.